Cortexyme to Present at National Academies Forum on Tuesday, June 11, 2019
June 10 2019 - 8:00AM
Business Wire
-- Event will be webcast, with Cortexyme
presentation expected to start at 2:05 p.m. EDT tomorrow
afternoon
Cortexyme, Inc. (Nasdaq: CRTX) today announced that Casey Lynch,
the company’s chief executive officer, chairman, and co-founder,
will present at a National Academies of Science, Engineering, and
Medicine workshop on the growing understanding of the relationship
between pathogens and chronic disease this week. Ms. Lynch will
provide an overview of Cortexyme’s work to pioneer a novel
disease-modifying therapeutic approach to treat a key underlying
cause of Alzheimer’s and other degenerative diseases during
“Breaking Down Silos: The Convergence of Infectious Diseases and
Noncommunicable Diseases,” which will be held June 11-12 in New
York.
In her remarks, Ms. Lynch will review the scientific rationale
and data supporting a key role for Porphyromonas gingivalis in the
development of Alzheimer’s disease, based on the identification of
the bacteria in the brain of Alzheimer’s patients and its ability
to cause neurodegeneration, inflammation, and other pathology
associated with Alzheimer’s in animal models. Preclinical and
clinical evidence indicates that treatment with Cortexyme’s
investigational gingipain inhibitor, COR388, may be beneficial in
slowing or stopping disease progression. In addition to reviewing
the company’s foundational publication in Science Advances earlier
this year, Ms. Lynch will highlight the design of the Phase 2/3
GAIN trial, Cortexyme’s large, international clinical study of
COR388 in subjects with mild to moderate Alzheimer’s disease.
“The National Academies’ Forum on Microbial Threats has
assembled a deep roster of government, academic, private sector,
and non-profit speakers to explore how the distinction between
infectious and noncommunicable diseases is breaking down, and what
that means for human health,” said Lynch. “Cortexyme appreciates
the opportunity to contribute to the conversation by sharing what
we’ve learned from our research into the bacterial hypothesis for
the development of Alzheimer’s, including the clinical experience
with COR388.”
The event will be webcast, with a live broadcast and archive of
individual presentations both expected to be available here. The
Cortexyme portion of the event is expected to begin at 2:05 p.m.
EDT / 11:05 a.m. PDT tomorrow, Tuesday, June 11, 2019, and will be
moderated by Julie Parsonnet, M.D., Professor of Health Research
and Policy at Stanford University. The full agenda for the
event is available here.
About Cortexyme, Inc.
Cortexyme (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering a novel disease-modifying
therapeutic approach to treat a key underlying cause of Alzheimer's
disease and other degenerative diseases. Cortexyme is
targeting a specific, infectious pathogen found in the brain of
Alzheimer’s patients and tied to neurodegeneration and
neuroinflammation in animal models. The company's lead
investigational medicine, COR388, is the subject of the GAIN trial,
an ongoing Phase 2/3 clinical study in patients with mild to
moderate Alzheimer’s disease. More information about the trial can
be found at www.GAINtrial.com. To learn more about Cortexyme, visit
www.cortexyme.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. Factors that could cause
actual results to differ include, but are not limited to, the risks
and uncertainties described in the section titled “Risk Factors” in
the final prospectus related to Cortexyme’s initial public offering
filed with the Securities and Exchange Commission on May 9,
2019. Forward-looking statements contained in this press release
are made as of this date, and Cortexyme undertakes no duty to
update such information except as required under applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190610005221/en/
Hal MackinsFor Cortexyme, Inc.hal@torchcomllc.com(415)
994-0040
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024